临床缓解毛细支气管炎患儿采用布地萘德联合胸腺肽干预对哮喘发病率的影响

目的:观察布地萘德气雾剂联合胸腺肽对降低毛细支气管炎(毛支)患儿哮喘发病率的作用。方法:急性毛支临床缓解患儿116例随机分成治疗组(54例)和对照组(62例)。治疗组采用布地萘德气雾剂200μg/d吸入,1次/d,胸腺肽20mg,im,1次/周,疗程3个月,观察1.5年时患儿哮喘发病率、首次喘息复发时间、喘息持续时间、干预治疗前后血清总IgE水平变化,并与对照组比较。结果:随访1.5年,治疗组哮喘发病率较对照组明显下降(χ2=19.063,P<0.01),平均首次喘息复发时间推迟(P<0.01),喘息持续时间缩短(P<0.01);随访0.5年治疗组血清总IgE水平恢复正常(P<0.05)。结论:急性毛支患儿临床缓解后吸入布地萘德气雾剂联合胸腺肽进行哮喘干预治疗,可明显降低哮喘发病率,值得临床推广。

Effect of Pulmicort Aerosol and Thymic Peptide on Intervention Asthma Morbidity after Clinical Relief of Bronchiolitis

Objective：To observe the function of putmicort aerosol and thymlc peptide reducting asthma morbidity of bronchiolitis. Methods： 116 cases after clinical relief of bronchiolitis were randomly divided into two groups： 54eases in the pulmieort aerosol and thymic peptide treatment group, 63 cases in the control grouP. The treatment group was treated with pulmieort aerosol （200μg/d, inhaled,once-daily, 3 months）and thymic peptide（20mg/w, im, 3 months）. It was observed for one and a half years that asthma morbidity and the first time of asthmatic replaying and the time of asthmatic continuing and the changed of serum IgE level was measured before and after treatment. Results： To be followed up one and a half years, asthma morbidity in treatment group was significantly reduced than in contorl group （x^2 = 19.062,P〈0. 01）, the first time of asthmatic replaying in the treatment group was significantly latered than in eontorl group（P〈0. 01）, the time of asthmatic eontitinuing in treatment group was significantly shorter than that in contorl group（P〈0. 01）. To be followed up half a year, serum IgE level in treatment group was returned to normal （P〈 0.05）. Conclusion： It can significantly reduce asthma morbidity after clinical relief of bronchiolitis with pulmicort aerosol and thymic peptide. It＇s worthy of extensive application for clinic work.